Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

$500 Million Upfront Payment to Activate the Partnership for Ivonescimab Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its…#summitsboardofdirectors #privatesecuritieslitigationreformact #maturitydates #cambridge #nsclc #februarymaturitydate #mainboardofstockexchange #summitscommonstock #riskfactors #securitiesandexchangecommission
Source: Reuters: Health - Category: Consumer Health News Source Type: news